coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)

被引：8
|
作者：
Paolo A Ascierto
Grant A. McArthur
Brigitte Dréno
James Larkin
Gabriella Liszkay
Michele Maio
Mario Mandala
Lev Demidov
Daniil Stroyakovskiy
Luc Thomas
Luis de la Cruz-Merino
Victoria Atkinson
Caroline Dutriaux
Claus Garbe
Ilsung Chang
Stephen P. Hack
Antoni Ribas
机构：
[1] Istituto Nazionale Tumori Fondazione G. Pascale,
[2] Peter MacCallum Cancer Centre,undefined
[3] Hôtel Dieu Place Alexis Ricordeau,undefined
[4] The Royal Marsden Hospital,undefined
[5] National Institute of Oncology,undefined
[6] Azienda Ospedaliera Universitaria Senese,undefined
[7] Papa Giovanni XXIII Hospital,undefined
[8] N.N. Blokhin Russian Cancer Research Center,undefined
[9] Moscow City Oncology Hospital 62,undefined
[10] Centre Hospitalier Lyon Sud,undefined
[11] Hospital Universitario Virgen Macarena,undefined
[12] Princess Alexandra Hospital,undefined
[13] Hopital Saint André,undefined
[14] University of Tübingen,undefined
[15] Genentech,undefined
[16] Inc,undefined
[17] Jonsson Comprehensive Cancer Center at the University of California,undefined
[18] Los Angeles,undefined
来源：
Journal of Translational Medicine | / 13卷 / Suppl 1期
关键词：
Overall Survival; Metastatic Melanoma; Vemurafenib; Creatine Phosphokinase; BRAF Inhibitor;
D O I：
10.1186/1479-5876-13-S1-O4
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 8 条
  • [1] Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation–positive melanoma
    Brigitte Dréno
    Paolo A Ascierto
    Victoria Atkinson
    Gabriella Liszkay
    Michele Maio
    Mario Mandalà
    Lev Demidov
    Daniil Stroyakovskiy
    Luc Thomas
    Luis de la Cruz-Merino
    Caroline Dutriaux
    Claus Garbe
    Karen Bartley
    Thomas Karagiannis
    Ilsung Chang
    Isabelle Rooney
    Daniel O Koralek
    James Larkin
    Grant A McArthur
    Antoni Ribas
    British Journal of Cancer, 2018, 118 : 777 - 784
  • [2] Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma
    Dreno, Brigitte
    Ascierto, Paolo A.
    Atkinson, Victoria
    Liszkay, Gabriella
    Maio, Michele
    Mandala, Mario
    Demidov, Lev
    Stroyakovskiy, Daniil
    Thomas, Luc
    de la Cruz-Merino, Luis
    Dutriaux, Caroline
    Garbe, Claus
    Bartley, Karen
    Karagiannis, Thomas
    Chang, Ilsung
    Rooney, Isabelle
    Koralek, Daniel O.
    Larkin, James
    McArthur, Grant A.
    Ribas, Antoni
    BRITISH JOURNAL OF CANCER, 2018, 118 (06) : 777 - 784
  • [3] Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study
    Lu Si
    Xiaoshi Zhang
    Zhen Xu
    Qiudi Jiang
    Lilian Bu
    Xuan Wang
    Lili Mao
    Weijiang Zhang
    Nicole Richie
    Jun Guo
    BMC Cancer, 18
  • [4] Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
    Ascierto, Paolo A.
    McArthur, Grant A.
    Dreno, Brigitte
    Atkinson, Victoria
    Liszkay, Gabrielle
    Di Giacomo, Anna Maria
    Mandala, Mario
    Demidov, Lev
    Stroyakovskiy, Daniil
    Thomas, Luc
    de la Cruz-Merino, Luis
    Dutriaux, Caroline
    Garbe, Claus
    Yan, Yibing
    Wongchenko, Matthew
    Chang, Ilsung
    Hsu, Jessie J.
    Koralek, Daniel O.
    Rooney, Isabelle
    Ribas, Antoni
    Larkin, James
    LANCET ONCOLOGY, 2016, 17 (09) : 1248 - 1260
  • [5] Vemurafenib in Chinese patients with BRAFV600 mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study
    Si, Lu
    Zhang, Xiaoshi
    Xu, Zhen
    Jiang, Qiudi
    Bu, Lilian
    Wang, Xuan
    Mao, Lili
    Zhang, Weijiang
    Richie, Nicole
    Guo, Jun
    BMC CANCER, 2018, 18
  • [6] Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
    Chapman, P. B.
    Robert, C.
    Larkin, J.
    Haanen, J. B.
    Ribas, A.
    Hogg, D.
    Hamid, O.
    Ascierto, P. A.
    Testori, A.
    Lorigan, P. C.
    Dummer, R.
    Sosman, J. A.
    Flaherty, K. T.
    Chang, I.
    Coleman, S.
    Caro, I.
    Hauschild, A.
    McArthur, G. A.
    ANNALS OF ONCOLOGY, 2017, 28 (10) : 2581 - 2587
  • [7] Survival in adult patients with BRAFV600 mutation-positive advanced melanoma: a noninterventional ambispective study of patients with cobimetinib combined with vemurafenib during the French early access program: MELANIS study
    Meyer, Nicolas
    Perol, David
    Duval-Modeste, Anne-Benedicte
    El Adaoui, Laila
    Lelarge, Yoann
    Niarra, Ralph
    Mateus, Christine
    MELANOMA RESEARCH, 2022, 32 (04) : 269 - 277
  • [8] A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES)
    Pinter, Tamas
    Klippel, Zandra
    Cesas, Alvydas
    Croitoru, Adina
    Decaestecker, Jochen
    Gibbs, Peter
    Hotko, Yevhen
    Jassem, Jacek
    Kurteva, Galina
    Novotny, Jan
    O'Reilly, Seamus
    Salek, Tomas
    Reiner, Maureen
    Morrow, Phuong Khanh
    Choi, Mi Rim
    Whittaker, Sadie
    Blanke, Charles
    CLINICAL COLORECTAL CANCER, 2017, 16 (02) : 103 - +
1